Plain-English translation of NCT03207009 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Beta-thalassemia research guide →Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial tested LentiGlobin BB305, a one-time gene therapy treatment for people with transfusion-dependent beta-thalassemia, a blood disorder that requires regular blood transfusions. The treatment works by taking some of your own stem cells, modifying them in a laboratory to produce healthy hemoglobin (the oxygen-carrying protein in blood), and then putting those modified cells back into your body. The trial examined whether this medication could reduce or eliminate the need for ongoing blood transfusions.
People with transfusion-dependent beta-thalassemia currently depend on regular blood transfusions to survive, which can lead to serious complications over time. This medication was developed to offer a potential one-time treatment that could give patients their own source of healthy blood cells, reducing or eliminating the need for lifelong transfusions.
Participants in this trial received medical preparation (chemotherapy conditioning) to prepare their body for the new stem cells, then received an infusion of their own genetically modified stem cells back into their bloodstream. After the treatment, participants were monitored closely through hospital visits and follow-up appointments to track how well the therapy worked, whether transfusions were still needed, and to watch for any side effects. The trial involved close medical supervision during the initial recovery period and ongoing monitoring to evaluate the long-term success of the treatment.
AI-generated summary from trial data · Aug 22, 2026 · Not medical advice
United States
France
Germany